BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

439 related articles for article (PubMed ID: 12072040)

  • 1. (99m)Technetium pentavalent dimercaptosuccinic acid scintigraphy in the follow-up of clinically nonfunctioning pituitary adenomas after radiotherapy.
    Colao A; Ferone D; Lombardi G; Lastoria S
    Clin Endocrinol (Oxf); 2002 Jun; 56(6):713-21. PubMed ID: 12072040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Technetium-99m pentavalent dimercaptosuccinic acid imaging in patients with pituitary adenomas.
    Lastoria S; Colao A; Vergara E; Ferone D; Varrella P; Merola B; Lombardi G; Salvatore M
    Eur J Endocrinol; 1995 Jul; 133(1):38-47. PubMed ID: 7627336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I-methoxybenzamide.
    Colao A; Ferone D; Lastoria S; Cerbone G; Di Sarno A; Di Somma C; Lucci R; Lombardi G
    Clin Endocrinol (Oxf); 2000 Apr; 52(4):437-45. PubMed ID: 10762286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The pituitary uptake of (111)In-DTPA-D-Phe1-octreotide in the normal pituitary and in pituitary adenomas.
    Colao A; Lastoria S; Ferone D; Varrella P; Marzullo P; Pivonello R; Cerbone G; Acampa W; Salvatore M; Lombardi G
    J Endocrinol Invest; 1999 Mar; 22(3):176-83. PubMed ID: 10219884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differentiation of pituitary adenomas from other sellar and parasellar tumors by 99mTc(V)-DMSA scintigraphy.
    Yamamura K; Suzuki S; Yamamoto I
    Neurol Med Chir (Tokyo); 2003 Apr; 43(4):181-6; discussion 187. PubMed ID: 12760496
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical usefulness of 99mTc-HYNIC-TOC, 99mTc(V)-DMSA, and 99mTc-MIBI SPECT in the evaluation of pituitary adenomas.
    Vukomanovic VR; Matovic M; Doknic M; Ignjatovic V; Simic Vukomanovic I; Djukic S; Peulic M; Djukic A
    Nucl Med Commun; 2019 Jan; 40(1):41-51. PubMed ID: 30334858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo imaging of pituitary tumours using a radiolabelled dopamine D2 receptor radioligand.
    de Herder WW; Reijs AE; Kwekkeboom DJ; Hofland LJ; Nobels FR; Oei HY; Krenning EP; Lamberts SW
    Clin Endocrinol (Oxf); 1996 Dec; 45(6):755-67. PubMed ID: 9039343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation of scintigraphic results using 123I-methoxybenzamide with hormone levels and tumor size response to quinagolide in patients with pituitary adenomas.
    Ferone D; Lastoria S; Colao A; Varrella P; Cerbone G; Acampa W; Merola B; Salvatore M; Lombardi G
    J Clin Endocrinol Metab; 1998 Jan; 83(1):248-52. PubMed ID: 9435450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pentavalent technetium-99m-dimercaptosuccinic acid [Tc-99m (V) DMSA] brain SPECT: does it have a place in predicting survival in patients with glioblastoma multiforme?
    Amin A; Mustafa M; Abd El-Hadi E; Monier A; Badwey A; Saad E
    J Neurooncol; 2015 Jan; 121(2):303-9. PubMed ID: 25349131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Results of somatostatin receptor scintigraphy do not predict pituitary tumor volume- and hormone-response to ocreotide therapy and do not correlate with tumor histology.
    Plöckinger U; Bäder M; Hopfenmüller W; Saeger W; Quabbe HJ
    Eur J Endocrinol; 1997 Apr; 136(4):369-76. PubMed ID: 9150695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Scintigraphic imaging of pituitary adenomas: an in vivo evaluation of somatostatin receptors.
    Oppizzi G; Cozzi R; Dallabonzana D; Orlandi P; Benini Z; Petroncini M; Attanasio R; Milella M; Banfi G; Possa M
    J Endocrinol Invest; 1998 Sep; 21(8):512-9. PubMed ID: 9801992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CT scan of pituitary adenomas.
    Sakoda K; Mukada K; Yonezawa M; Matsumura S; Yoshimoto H; Mori S; Uozumi T
    Neuroradiology; 1981 Jan; 20(5):249-53. PubMed ID: 7465044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of Tc-99m (V) DMSA scintigraphy in the diagnosis and follow-up of lung cancer lesions.
    Ergün EL; Kara PO; Gedik GK; Kars A; Türker A; Caner B
    Ann Nucl Med; 2007 Jul; 21(5):275-83. PubMed ID: 17634845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Somatostatin receptor imaging in somatotroph and non-functioning pituitary adenomas: correlation with hormonal and visual responses to octreotide.
    Broson-Chazot F; Houzard C; Ajzenberg C; Nocaudie M; Duet M; Mundler O; Marchandise X; Epelbaum J; Gomez De Alzaga M; Schäfer J; Meyerhof W; Sassolas G; Warnet A
    Clin Endocrinol (Oxf); 1997 Nov; 47(5):589-98. PubMed ID: 9425399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endocrinological outcome following first time transsphenoidal surgery for GH-, ACTH-, and PRL-secreting pituitary adenomas.
    Kristof RA; Schramm J; Redel L; Neuloh G; Wichers M; Klingmüller D
    Acta Neurochir (Wien); 2002 Jun; 144(6):555-61; discussion 561. PubMed ID: 12111488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [111In-DTPA-D-Phe]-octreotide scintigraphy in functioning and non-functioning pituitary adenomas.
    Boni G; Ferdeghini M; Bellina CR; Matteucci F; Castro Lopez E; Parenti G; Canapicchi R; Bianchi R
    Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):90-3. PubMed ID: 9002759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of Microsurgical Sublabial Approach (MSA) Versus Endoscopic Endonasal Approach (EEA) for the Treatment of Pituitary Adenomas Based on Radiological and Hormonal Outcome.
    Mattogno PP; Mangiola A; Lofrese G; Vigo V; Anile C
    Acta Neurochir Suppl; 2017; 124():101-106. PubMed ID: 28120060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of In-111 octreotide and Tc-99m (V) DMSA scintigraphy in the detection of medullary thyroid tumor foci in patients with elevated levels of tumor markers after surgery.
    Arslan N; Ilgan S; Yuksel D; Serdengecti M; Bulakbasi N; Ugur O; Ozguven MA
    Clin Nucl Med; 2001 Aug; 26(8):683-8. PubMed ID: 11452174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fractionated stereotactic conformal radiotherapy for secreting and nonsecreting pituitary adenomas.
    Minniti G; Traish D; Ashley S; Gonsalves A; Brada M
    Clin Endocrinol (Oxf); 2006 May; 64(5):542-8. PubMed ID: 16649974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preoperative octreotide treatment of growth hormone-secreting and clinically nonfunctioning pituitary macroadenomas: effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy.
    Plöckinger U; Reichel M; Fett U; Saeger W; Quabbe HJ
    J Clin Endocrinol Metab; 1994 Nov; 79(5):1416-23. PubMed ID: 7962337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.